ArticleThe American journal of tropical medicine and hygiene2016
Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.
Article in The American journal of tropical medicine and hygiene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Productivity costs from a dengue episode in Asia: a systematic literature review.BMC infectious diseases · 2020Pooled it
- Trends in dengue research in the Philippines: A systematic review.PLoS neglected tropical diseases · 2019Pooled it
- Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.The American journal of tropical medicine and hygiene · 2017Trial
- Time-dependent force of infection and effective reproduction ratio in an age-structure dengue transmission model in Bandung City, Indonesia.Infectious Disease Modelling · 2022Article
- Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.PLoS neglected tropical diseases · 2021Article
- The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.PLoS neglected tropical diseases · 2020Article
- Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs withInternational journal of environmental research and public health · 2020Article
- Hidden heterogeneity and its influence on dengue vaccination impact.Infectious Disease Modelling · 2020Article
- Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.PLoS neglected tropical diseases · 2019Article
- SIR Model for Dengue Disease with Effect of Dengue Vaccination.Computational and mathematical methods in medicine · 2018Article
- An economic evaluation of vector control in the age of a dengue vaccine.PLoS neglected tropical diseases · 2017Article
- Cost-Effectiveness of Dengue Vaccination Programs in Brazil.The American journal of tropical medicine and hygiene · 2017Article
- Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is one of the most problematic vector-borne diseases in the Philippines, with an estimated 842,867 cases resulting in medical costs of $345 million U.S. dollars annually. In December 2015, the first dengue vaccine, known as chimeric yellow fever virus-dengue virus tetravalent dengue vaccine, was approved for use in the Philippines and is given to children 9 years of age. To estimate the cost-effectiveness of dengue vaccination in the Philippines, we developed an age-structured model of dengue transmission and vaccination. Using our model, we compared two vaccination scenarios entailing routine vaccination programs both with and without catch-up vaccination. Our results indicate that the higher the cost of vaccination, the less cost-effective the dengue vaccination program. With the current dengue vaccination program that vaccinates children 9 years of age, dengue vaccination is cost-effective for vaccination costs up to $70 from a health-care perspective and up to $75 from a societal perspective. Under a favorable scenario consisting of 1 year of catch-up vaccinations that target children 9-15 years of age, followed by regular vaccination of 9-year-old children, vaccination is cost-effective at costs up to $72 from a health-care perspective and up to $78 from a societal perspective. In general, dengue vaccination is expected to reduce the incidence of both dengue fever and dengue hemorrhagic fever /dengue shock syndrome. Our results demonstrate that even at relatively low vaccine efficacies, age-targeted vaccination may still be cost-effective provided the vaccination cost is sufficiently low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.